About Course #Y8004
Start Date: September 10, 2019
Expiration Date: September 10, 2022
Clinicians play an important role in managing patients with these conditions who are eligible for high-risk pharmacologic therapies, such as thrombolytics. Specific knowledge of the general information and caveats associated with thrombolytic therapy is vital for optimal patient care outcomes to be achieved. This course is designed for clinicians who provide care to patients currently prescribed thrombolytic medications.
The purpose of this course is to increase clinicians" knowledge of thrombolytic medications so that they can identify the optimal therapy and safely use these medications. Pharmacotherapy is rapidly changing, new pharmaceutical agents are continuously being developed and approved, and older agents are being investigated in new ways; therefore, the clinician should stay abreast of new medications and ongoing research findings and their implications in the delivery of patient care.
Universal Activity Number (UAN) - 0607-0000-19-012-H01-P
Type of Activity - Knowledge
Topic Designator - 01 - Disease State Management/Drug Therapy
- Identify the relevant pharmacokinetic and pharmacodynamics properties of thrombolytics.
- Identify and apply the contemporary role of thrombolytics for management of acute ischemic strokes.
- Describe evidence supporting the use of thrombolytics in acute myocardial infarction.
- Describe the most appropriate population to receive thrombolytics for treating acute pulmonary embolism.
- Describe key patient selection and monitoring that can ensure optimal patient outcomes.
- Describe how a pharmacist can use this information to optimize patient outcomes.
About the Author(s)
William L. Baker, PharmD, FCCP, FACC, BCPS-AQ Cardiology, is an Assistant Professor of Pharmacy Practice at the University of Connecticut (UConn) School of Pharmacy in Storrs, Connecticut. Dr. Baker received his BS in Pharmacy Studies and Doctor of Pharmacy (PharmD) degrees from the UConn School of Pharmacy in 2000 and 2002, respectively. After being in clinical practice for a number of years, he completed a 2-year cardiovascular pharmacology and outcomes research fellowship at Hartford Hospital in Hartford, Connecticut (2006-2008). He has been on faculty with the UConn School of Pharmacy since 2009.
- Courses must be completed on or before the expiration date noted in the course description above.
- You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
- Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools' policy not to accept commercial support.
- All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.
Find Thrombolytic Therapy: Implications for Patient Management - Y8004 in your state
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Rhode Island
- South Carolina
- South Dakota
- West Virginia